Randomized Trial of Glutathione with Anti-PD-1 and Chemotherapy in Advanced NSCLC

Launched by THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring whether a substance called glutathione can make current treatments for advanced non-small cell lung cancer (NSCLC) more effective. NSCLC is a common type of lung cancer, and the study aims to see if adding glutathione to standard chemotherapy and immunotherapy (which helps the immune system fight cancer) can improve treatment outcomes. Researchers believe that glutathione might help boost the immune response against the cancer, potentially leading to better patient survival.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with either lung squamous cell carcinoma or adenocarcinoma. You should also have experienced disease progression after your first round of chemotherapy or chemo-immunotherapy. However, patients with other types of lung cancer, those who have stopped treatment, or women who are pregnant or breastfeeding cannot join the study. If you are eligible, you can expect to receive treatment and monitoring as part of the trial to help researchers understand how well glutathione works in combination with existing therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically or cytologically confirmed diagnosis of lung squamous cell carcinoma or adenocarcinoma.
• • 2. Documented disease progression following first-line chemotherapy or chemo-immunotherapy.
• • 3. Age ≥18 years at the time of enrollment.
• Exclusion Criteria:
• • 1. Patients with small cell lung cancer or other histological subtypes of lung cancer.
• • 2. Patients lost to follow-up, who discontinued treatment, or died within one year of diagnosis.
• • 3. Pregnant or lactating women